Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

SQZ

SQZ Biotechnologies (SQZ)

SQZ Biotechnologies Company
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:SQZ
DataHoraFonteTítuloCódigoCompanhia
06/05/202407:25GlobeNewswire Inc.Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderNYSE:SQZSQZ Biotechnologies Company
23/01/202418:31Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNYSE:SQZSQZ Biotechnologies Company
22/12/202319:18Edgar (US Regulatory)Form 8-K - Current reportNYSE:SQZSQZ Biotechnologies Company
08/11/202318:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:SQZSQZ Biotechnologies Company
15/06/202317:47Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:SQZSQZ Biotechnologies Company
15/06/202317:38Edgar (US Regulatory)Current Report Filing (8-k)NYSE:SQZSQZ Biotechnologies Company
15/06/202317:30Business WireSQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock SplitNYSE:SQZSQZ Biotechnologies Company
10/05/202317:45Business WireSQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
10/05/202317:35Edgar (US Regulatory)Quarterly Report (10-q)NYSE:SQZSQZ Biotechnologies Company
05/05/202317:32Edgar (US Regulatory)Annual Report to Security Holders (ars)NYSE:SQZSQZ Biotechnologies Company
26/04/202317:32Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:SQZSQZ Biotechnologies Company
26/04/202317:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:SQZSQZ Biotechnologies Company
10/04/202317:32Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:SQZSQZ Biotechnologies Company
22/03/202317:50Business WireSQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical TrialNYSE:SQZSQZ Biotechnologies Company
22/03/202317:45Business WireSQZ Biotechnologies Reports Full Year 2022 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
14/02/202316:25Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:SQZSQZ Biotechnologies Company
18/01/202318:30Business WireSQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock ExchangeNYSE:SQZSQZ Biotechnologies Company
06/12/202213:55TipRanksSQZ Biotechnologies (SQZ) Gets a Hold from H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
06/12/202210:55TipRanksSQZ Biotechnologies (SQZ) Receives a Buy from Brookline Capital MarketsNYSE:SQZSQZ Biotechnologies Company
06/12/202208:45Business WireSQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology CongressNYSE:SQZSQZ Biotechnologies Company
02/12/202208:15TipRanksSQZ Biotechnologies (SQZ) was downgraded to a Hold Rating at H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
01/12/202209:55TipRanksChardan Capital Sticks to Their Buy Rating for SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
30/11/202218:30Business WireSQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive OfficerNYSE:SQZSQZ Biotechnologies Company
10/11/202211:00Business WireSQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual MeetingNYSE:SQZSQZ Biotechnologies Company
10/11/202208:17TipRanksSQZ Biotechnologies (SQZ) Receives a Buy from H.C. WainwrightNYSE:SQZSQZ Biotechnologies Company
09/11/202221:55TipRanksBrookline Capital Markets Reaffirms Their Buy Rating on SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
09/11/202218:30Business WireSQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio UpdatesNYSE:SQZSQZ Biotechnologies Company
03/10/202207:45Business WireSQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived ImmunotherapyNYSE:SQZSQZ Biotechnologies Company
12/09/202210:15TipRanksBrookline Capital Markets Keeps Their Buy Rating on SQZ Biotechnologies (SQZ)NYSE:SQZSQZ Biotechnologies Company
12/09/202207:00Business WireSQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell TherapiesNYSE:SQZSQZ Biotechnologies Company
 Apresentando as notícias mais relevantes sobre:NYSE:SQZ